Optical imaging probes in oncology

Abstract

Cancer is a complex disease, characterized by alteration of different physiological molecular processes and cellular features. Keeping this in mind, the possibility of early identification and detection of specific tumor biomarkers by non-invasive approaches could improve early diagnosis and patient management.Different molecular imaging procedures provide powerful tools for detection and non-invasive characterization of oncological lesions. Clinical studies are mainly based on the use of computed tomography, nuclear-based imaging techniques and magnetic resonance imaging. Preclinical imaging in small animal models entails the use of dedicated instruments, and beyond the already cited imaging techniques, it includes also optical imaging studies. Optical imaging strategies are based on the use of luminescent or fluorescent reporter genes or injectable fluorescent or luminescent probes that provide the possibility to study tumor features even by means of fluorescence and luminescence imaging. Currently, most of these probes are used only in animal models, but the possibility of applying some of them also in the clinics is under evaluation.The importance of tumor imaging, the ease of use of optical imaging instruments, the commercial availability of a wide range of probes as well as the continuous description of newly developed probes, demonstrate the significance of these applications. The aim of this review is providing a complete description of the possible optical imaging procedures available for the non-invasive assessment of tumor features in oncological murine models. In particular, the characteristics of both commercially available and newly developed probes will be outlined and discussed.

Amine Landscaping to Maximize Protein-Dye Fluorescence and Ultrastable Protein-Ligand Interaction

“…Given the relative protein dimensions, the low dye number for optimal streptavidin brightness is consistent with the four to six dyes optimal for antibody brightness ( Vira et al., 2010 ). Brightness is a precious commodity for temporal and spatial resolution in super-resolution microscopy and diagnostic sensitivity ( Liu et al., 2015 , Martelli et al., 2016 ). Notably, dye-NHS labeling of streptavidin led to poor brightness and utility in MHC-tetramer monitoring of immune responses ( Davis et al., 2011 , Ramachandiran et al., 2007 ).…”

Safety markers for rhabdomyosarcoma cells using an in�vivo imaging system

“…In this technique, the substrate luciferin is injected into mice in the presence of ATP and oxygen. However, bioluminescence imaging has disadvantages, including instability, fast decay and toxicity (20). Fluorescence imaging uses fluorescent reporter gene labeling and is excited by excitation of fluorescent groups to achieve high energy; this technique emits light in a simple and intuitive manner.…”

In Vivo Follow-up of Brain Tumor Growth via Bioluminescence Imaging and Fluorescence Tomography

“…Fluorescence tomography thus results from a complex, multi-step process using light wavelengths in the NIR windows, multiple acquisitions of the fluorescent signal with different geometry, tissue absorption measurement, and complex reconstruction algorithms to determine both absorption and fluorescent maps. Many chemical fluorophores are now available that are compatible with NIR tomographs, enabling a large range of imaging strategies in oncology, including those based on the use of blood pool agents, specific probes, or endogenous enzyme-activable probes [9]. For reporter gene strategies, efforts to discover and to engineer NIR-fluorescent proteins have resulted in reports on several fluorescent proteins to be used for whole-body imaging using NIR tomographs, including IFP1.4 [10] and iRFP [6,7].…”